SAN DIEGO, Jan. 6, 2016 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced the Company's participation at the
34th Annual J.P. Morgan Healthcare Conference.
On Wednesday, January 13, 2016,
Sequenom will hold investor meetings at the 34th Annual
J.P. Morgan Healthcare Conference, to be held at the St. Francis
Hotel in San Francisco, CA.
Investors wishing to schedule a meeting with Sequenom should
contact their J.P. Morgan representative or the Sequenom contacts
listed above. The company's investor presentation will be
given at 4 pm Pacific time that day
by Dr. Dirk van den Boom, President
and Chief Executive Officer, and will be webcast on the company's
website, www.sequenom.com/investors, and available for 90 days at
the following link:
http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=19842
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information. To learn how
Sequenom is interpreting the genome to improve your life, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories, a CAP-accredited and CLIA-certified
molecular diagnostics laboratory, has developed a broad range of
laboratory tests, with a focus principally on prenatal care.
Branded under the names HerediT®, HerediT®
UNIVERSAL, MaterniT® GENOME, MaterniT21®
PLUS, NextView®, SensiGene® and
VisibiliT™, these molecular genetic laboratory-developed
tests provide early patient management information for
obstetricians, geneticists, and maternal fetal medicine
specialists. Sequenom Laboratories is changing the landscape in
genetic diagnostics using proprietary cutting edge technologies.
Visit www.laboratories.sequenom.com and follow @SequenomLabs.
SEQUENOM®, HerediT®,
MaterniT® GENOME,
MaterniT21® PLUS, NextView®,
SensiGene®, VisibiliT™ and Sequenom
Laboratories™ are trademarks of Sequenom, Inc. All
other trademarks and service marks are the property of their
respective owners.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-inc-announces-participation-at-the-34th-annual-jp-morgan-healthcare-conference-300200506.html
SOURCE Sequenom, Inc.